Microbial contamination of hematopoietic progenitor cell products: clinical outcome

TitleMicrobial contamination of hematopoietic progenitor cell products: clinical outcome
Publication TypeJournal Article
Year of Publication2007
AuthorsPatah PA, Parmar S, McMannis J, Sadeghi T, Karandish S, Rondon G, Tarrand J, Champlin R, de Lima M, Shpall EJ
Date PublishedAug
ISSN0268-3369; 0268-3369
Accession NumberPMID: 17572714; 1705731 [pii]
KeywordsAntibiotic Prophylaxis / methods, Bacteremia / prevention & control, Blood Component Removal / methods, Cross Infection / microbiology / prevention & control, Hematopoietic Stem Cell Transplantation / adverse effects, Hematopoietic Stem Cells / microbiology, Humans, Medical Audit, Retrospective Studies, Texas, Transplantation, Autologous, Transplantation, Homologous

We reviewed the results of routine microbiological assays of 3078 infused hematopoietic progenitor cell (HPC) products for autologous and allogeneic transplantation between January 2001 and December 2005. Thirty-seven (1.2%) contaminated products were found. All patients receiving contaminated infusions received empirical antibiotic prophylaxis according to the assay result. None of these patients developed a positive blood culture with the same agent, developed infections that could be attributable to the contaminated product or experienced any clinical sequelae. Coagulase-negative Staphylococcus was found in 32 (86.5%) products. Admission lengths and time to engraftment were within the expected time frame for autologous and allogeneic transplants. Microbial contamination of HPC products occurs at a low frequency; prophylactic use of antibiotics based on the microbiological assay appears to be effective in preventing clinical complications.

Alternate JournalBone Marrow Transplant.
Notify Library Reference ID1778